Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection

Annals of Internal Medicine

Volumn 132, Issue 3, 2000, Pages 201-205

  Yangco, Bienvenido G ^a   Von Bargen, Jennifer C ^b   Moorman, Anne C ^b   Holmberg, Scott D ^b  

^a Mailstop E 45 ^*  (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ARTICLE; CHEMOPROPHYLAXIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

EID: 0034141846     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-3-200002010-00005     Document Type: Article

References (11)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Von Bargen JC, Moorman AC Holmberg SD. How many pills do patients with HIV infection take? [Letter] JAMA. 1998;280:29.
3. Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD. Pneumocystis carinii pneumonia incidence and prophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:182-8,
4. Moorman AC, Holmberg SD, Marlowe SI, Von Bargen JC, Yangco BG, Palella FJ, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patents: The HIV Outpatient Study (HOPS). Ann Epidemiol. 1999;9:349-57.
5. Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman Al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia m HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet. 1999;353:201-3.
6. Lopez JC, Peña JM, Miro JM, Podzamczer D. Discontinuation of PCP prophylaxis (PRO) is safe in HIV-infected patients (PTS) with immunologic recovery with HAART [Abstract]. GESIDA 04/98 Study Group. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, 31 Jan-4 Feb 1999, Chicago. Alexandria, VA: Foundation for Retrovirology and Human Health; 1999.
7. García Vâzquez E, De Górgolas M, Garcia Delgado R, Fernández Guerrero ML. Is PCP prophylaxis needed in patients on highly active antiretroviral therapy with increasing CDA count? [Abstract] In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 Sept 1998; San Diego. Washington, DC, American Soc for Microbiology; 1998.
8. Maradona JA, Rodríguez-Guardado A, Carton JA, Asensi V, Casado L. Pneumocystis carinii prophylaxis withdrawal in highly active antirelroviral therapy responsive patients [Abstract], In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 Sept 1998, San Diego. Washington, DC: American Soc for Microbiology; 1998.
9. Ravaux I, Quinson AM, Chadapaud S, Gallais H. Discontinue primary and secondary prophylaxis regimens in selected HIV-infected patients treated with HAART [Abstract] In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 Sept 1998, San Diego. Washington, DC: American Soc for Microbiology; 1998.
10. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study N Engl J Med 1999;340:1301-6.
11. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: US Public Health Service (USPHS) and Infectious Disease Society of America (IDSA) MMWR Morb Mortal Wkly Rep 1999;48(RR-10):4-10.